Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
APM Stock Forecast 2026-2027
$0.86
Current Price
$6.99M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to APM Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
APM Price Momentum
-14.9%
1 Week Change
+1.2%
1 Month Change
-25.2%
1 Year Change
-18.9%
Year-to-Date Change
-80.8%
From 52W High of $4.47
+32.0%
From 52W Low of $0.65
📊 TOP ANALYST CALLS
Did APM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aptorum is one of their latest high-conviction picks.
Latest APM Stock Price Targets & Analyst Predictions
APM has shown a year-to-date change of -18.9% and a 1-year change of -25.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for APM. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
APM Analyst Ratings
0
Buy
0
Hold
0
Sell
APM Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.86
Latest APM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for APM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 7, 2022 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $8.00 |
| Apr 2, 2019 | China Renaissance | Buy | Initiates | $22.00 |
Aptorum Group Ltd. (APM) Competitors
The following stocks are similar to Aptorum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
APM
Aptorum Group
mkt cap
6.99M
Aptorum Group Ltd. (APM) Financial Data
Aptorum Group Ltd. has a market capitalization of $6.99M with a P/E ratio of 2.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -10.8%.
Valuation Metrics
Market Cap
$6.99M
Enterprise Value
$-2,020,248
P/E Ratio
2.8x
PEG Ratio
-1.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+49.4%
Current Ratio
0.8x
Debt/Equity
25.0x
ROE
-10.8%
ROA
-6.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aptorum Group Ltd. (APM) Business Model
About Aptorum Group Ltd.
What They Do
Develops biopharmaceuticals for unmet medical needs.
Business Model
The company operates on a dual business model focused on both therapeutics and non-therapeutics. It generates revenue through the development and commercialization of therapeutic assets targeting oncology, infectious diseases, and metabolic disorders, along with providing healthcare services and diagnostics.
Additional Information
Aptorum Group Ltd. is actively advancing several key pipeline candidates, including SACT-1 for neuroblastoma and ALS-4 for bacterial infections, both in phase 1 trials. The company also engages in preclinical programs to enhance rapid pathogen diagnostics and address urgent medical needs, indicating a strong commitment to biopharmaceutical innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1
CEO
Mr. Chung Yuen Huen
Country
United Kingdom
IPO Year
N/A
Website
www.aptorumgroup.comAptorum Group Ltd. (APM) Latest News & Analysis
Latest News
Quick Summary
Aptorum Group Limited (NASDAQ: APM) announced that shareholders approved a merger with DiamiR Biosciences Corp., a company focused on blood-based diagnostic tests, on June 9, 2026.
Why It Matters
The merger indicates potential growth and innovation for Aptorum Group, enhancing its product pipeline and market position, which could lead to increased investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Andean Precious Metals Corp. held its Q4 2025 earnings call, discussing financial performance and operational updates. Details on earnings and future outlook were provided.
Why It Matters
The Q4 2025 earnings call for Andean Precious Metals Corp. provides insights into financial performance, growth prospects, and market conditions, influencing investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aptorum Group (NASDAQ: APM) and DiamiR Biosciences announced a paper on microRNA-based glioblastoma biomarkers published in the journal Diagnostics.
Why It Matters
The publication of research on glioblastoma biomarkers enhances Aptorum's credibility, potentially attracting investment interest and influencing stock performance in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aptorum Group, DiamiR Biosciences, and Instant NanoBiosensors announced a collaboration to validate INB's automated APOE testing platform for clinical use in DiamiR's accredited laboratory.
Why It Matters
The collaboration between DiamiR and INB enhances diagnostic capabilities, potentially boosting revenue and market position, which could positively impact Aptorum's stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
DiamiR Biosciences and Aptorum Group will present posters at the CTAD Conference from December 1-4, 2025, focusing on blood-based diagnostics for brain health and other diseases.
Why It Matters
The announcement of poster presentations at a major Alzheimer's conference highlights potential advancements in diagnostics and treatments, signaling growth opportunities and influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Andean Precious Metals Corp. will host its Q3 2025 earnings call on November 12, 2025, at 9:00 AM EST, featuring key executives and analysts from various financial institutions.
Why It Matters
The earnings call indicates upcoming insights into Andean Precious Metals' financial performance, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About APM Stock
What is Aptorum Group Ltd.'s (APM) stock forecast for 2026?
Analyst forecasts for Aptorum Group Ltd. (APM) are not currently available. The stock is trading at $0.86.
Is APM stock a good investment in 2026?
Analyst ratings for APM are not currently available. The stock is currently trading at $0.86. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for APM stock?
Price predictions from Wall Street analysts for APM are not currently available. The stock is trading at $0.86.
What is Aptorum Group Ltd.'s business model?
The company operates on a dual business model focused on both therapeutics and non-therapeutics. It generates revenue through the development and commercialization of therapeutic assets targeting oncology, infectious diseases, and metabolic disorders, along with providing healthcare services and diagnostics.
What is the highest forecasted price for APM Aptorum Group Ltd.?
Price targets from Wall Street analysts for APM are not currently available. The stock is trading at $0.86.
What is the lowest forecasted price for APM Aptorum Group Ltd.?
Price targets from Wall Street analysts for APM are not currently available. The stock is trading at $0.86.
What is the overall APM consensus from analysts for Aptorum Group Ltd.?
Analyst ratings for APM are not currently available. The stock is trading at $0.86.
How accurate are APM stock price projections?
Stock price projections, including those for Aptorum Group Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 4:51 AM UTC